[Skip to Content]
[Skip to Content Landing]
Editor's Correspondence
March 12, 2007

Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials—Reply

Arch Intern Med. 2007;167(5):514-515. doi:10.1001/archinte.167.5.514

In reply

Although it was described that the study was done in a single hospital, I requested my physician colleagues of other nearby hospitals to participate in the 2 studies. Therefore, regarding the study on AD,1 we actually had 2 collaborating hospitals, and each of them followed 195 and 93 patients. The remaining 212 patients were followed at Mitate Hospital, Tagawa, Japan. Similarly, in the stroke study,2 the 2 collaborating hospitals followed 123 and 81 patients, and the remaining 76 patients were from Mitate Hospital. I apologize for confusing the readers of the ARCHIVES by not providing the numbers of patients in other hospitals involved in the studies. The authors did not describe this fact, the reason being that these hospitals were reluctant to have their names in the article. Diagnosis of AD was performed by myself and another neurologist who was not an active member of the study. I saw many neurological patients 6 days a week and performed follow-up assessment of patients with AD or stroke. However, 3 clinical psychologists performed the Mini-Mental State Examination on each patient with AD, and the Barthel index was assessed by 2 occupational therapists. This fact was not described in the article. The average number of the study subjects who visited each of the 3 hospitals ranged from 8 to 14 patients per day.